Highlights LIDDS AB

Equities

LIDDS

SE0001958612

Market Closed - Nasdaq Stockholm Other stock markets 17:00:00 25/06/2024 BST			5-day change	1st Jan Change
0.142 ^SEK	+12.70%		+12.70%	+31.48%

05-30	LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-26	LIDDS AB Moves the Publication of the Interim Report for the First Quarter 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2024	05-30	CI
Sweden's Lidds Finalizes Purchase of Noviga Research	03-21	MT
LIDDS AB (OM:LIDDS) completed the acquisition of Noviga Research AB.	03-20	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
LIDDS AB (OM:LIDDS) signed an agreement to acquire Noviga Research AB.	01-28	CI
Lidds CFO to Take Over CEO Role; Shares Plunge	11-28	MT
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-28	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	30/08/23	CI
LIDDS AB Announces Closure of R&D Project with Johnson & Johnson Enterprise Innovation Inc	06/07/23	CI
LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2023	29/05/23	CI
LIDDS AB Reports Earnings Results for the Full Year Ended December 31, 2022	13/03/23	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	13/03/23	CI
LIDDS AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	28/11/22	CI
LIDDS AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	25/08/22	CI
LIDDS Patent Covering the NanoZolid® Production Process Granted in Israel	08/07/22	CI
LIDDS AB Reports Earnings Results for the First Quarter Ended March 31, 2022	24/05/22	CI
LIDDS AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2021	23/02/22	CI
LIDDS AB Next Step with Nanozolid® Formulated Docetaxel	21/02/22	CI
LIDDS AB Announces the R&D Project with Johnson & Johnson Enterprise Innovation Inc	11/01/22	CI
LIDDS AB Announces Positive Topline Results from the Phase I Dose-Escalating Study of NanoZolid-Formulated Docetaxel	29/12/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights LIDDS AB

Equities

LIDDS

SE0001958612

Highlights

Filters